HENDERSON, NV, Sept. 26, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – BioLife Sciences (OTCPK: BLFE) is pleased to announce that it has entered into negotiations with Canadian Firm–Work In Motion towards the development and commercialization of custom designed copper infused bamboo gardening gloves for international distribution through Work In Motion’s extensive wholesale and distribution networks.
BioLife Sciences is contemplated to assume sole responsibility for the development and commercialization of copper infused bamboo gardening gloves as a private label design product framed around Work In Motion provided branding assets.
Industry standard, bamboo gardening gloves offer the inherent benefit of breathability, flexibility, and the reduction of sweat, while providing a thicker barrier than standard gloves alongside increased durability and cushioning. These well-known benefits would be paired with BioLife’s MFusion process infusing antimicrobial copper into every fiber of the gloves.
About BioLife Sciences Inc.
BioLife Sciences Inc. specializes in moving innovative products from the lab or small-scale production into wider market adoption. Its core business develops, licenses and distributes antimicrobial products and disruptive technology. One of BioLife Sciences’ core building block strategies is to develop, partner and assist innovative companies with the commercialization of leading-edge technologies.
About Work In Motion
Work In Motion is a leading products distributor, headquartered in Canada working in alliance with industry leading manufacturers sourcing multidisciplinary products connecting international distribution chains alongside custom product development and private label services.
Disclaimer
The information in this news release includes certain information and statements about management’s view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward-looking statements. Forward-looking statements in this news release include, but are not limited to, the ability of the Corporation to complete a qualifying transaction. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Corporation believes that the expectations reflected in forward looking statements are reasonable, it can give no assurance that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.
Contact Information:
www.biolifesciences.com
ir@biolifesciences.com
US & Canada: 1 (833) 919-1037
Toronto, Ontario--(Newsfile Corp. - July 4, 2024) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE)…
MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) -- Global biotechnology leader CSL Behring (ASX: CSL)…
SKYSCRAPER-06 evaluating tiragolumab plus Tecentriq and chemotherapy did not meet the primary endpoints of progression-free…
ICPO Center NuMeRI ICPO Foundation signed the contract with Nuclear Medicine Research Infrastructure (NuMeRI) to…
NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM)…
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 04, 2024 (GLOBE NEWSWIRE) -- HUTCHMED…